<?xml version="1.0" encoding="UTF-8"?><!-- generator="WordPress/2.9.2" -->
<rss version="0.92">
<channel>
	<title>BioHealth Investor</title>
	<link>http://www.biohealthinvestor.com</link>
	<description>Biotech and Medical Business Information</description>
	<lastBuildDate>Wed, 10 Mar 2010 20:02:44 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	
	<item>
		<title>High Hopes on Ariad (ARIA, MRK)</title>
		<description><![CDATA[Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings.  The difference here is that Ariad&#8217;s increased trading is in both the stock and in the bonds.  
Joe Kunkle of OptionsHawk.com noted, &#8220;implied volatility is 10% higher to 87.8% as shares gain 2.7%, 4,140 calls trading, [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/high-hopes-on-ariad-aria-mrk.html</link>
			</item>
	<item>
		<title>More Drug and BioHealth Dividends (MRX, WCRX, AMGN, MRK, PFE, PPH, BBH)</title>
		<description><![CDATA[Medicis (NYSE: MRX), a specialty pharmaceutical company in treatments of dermatological and aesthetic conditions, has the talk going again about dividends in the drug and biotech sector.  The company declared a quarter-end cash quarterly dividend of $0.06 payable on April 30, 2010 for holders of record at the close of business on April 1, 2010.  [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/more-drug-and-biohealth-dividends-mrx-wcrx-amgn-mrk-pfe-pph-bbh.html</link>
			</item>
	<item>
		<title>The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI)</title>
		<description><![CDATA[Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009.  The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB).  Abbott Laboratories (NYSE: ABT) announced last night that it entered into a definitive agreement for $27.00 per share in a cash buyout.  [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/the-facet-biotech-buyout-saga-fact-biib-abt-pdli.html</link>
			</item>
	<item>
		<title>EDAP TMS, Back on the Map (EDAP)</title>
		<description><![CDATA[EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company&#8217;s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration.  Because this market is still under-served, we wanted to look [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/edap-tms-back-on-the-map-edap.html</link>
			</item>
	<item>
		<title>Amylin &amp; Friends Brace for Diabetes Review (AMLN, LLY, ALKS)</title>
		<description><![CDATA[Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week.  This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes.  The date had been moved due [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/amylin-friends-brace-for-diabetes-review-amln-lly-alks.html</link>
			</item>
	<item>
		<title>The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)</title>
		<description><![CDATA[The biotech and biohealth universe is changing in size.  In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion.  At one point there were only about 10 or 11 in our [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/the-changing-landscape-of-biotech-valuations-acor-cbst-mnkd-incy-sgen-itmn-ipxl-mrx-svnt-vphm.html</link>
			</item>
	<item>
		<title>When Biotech Layoffs Come (XNPT)</title>
		<description><![CDATA[When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee.  That leaves more income and ultimately brings more dividends down the road.  But biotech firms are far from being thought of in the [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/when-biotech-layoffs-come-xnpt.html</link>
			</item>
	<item>
		<title>Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)</title>
		<description><![CDATA[BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors.  But sometimes there is a much larger bit of data either north of the border or in Europe.  There is a company called  Resverlogix Corp. which trades in Canada under the ticker &#8216;RVX&#8217; and the stock also trades in the US [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/winning-from-boosting-good-cholesterol-rvxcf-rvx-pfe-azn-mrk.html</link>
			</item>
	<item>
		<title>Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)</title>
		<description><![CDATA[Today&#8217;s price moves in the biotech sector are quite different from what we saw earlier this week.  A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week.  So much that other investors were going back over buyout candidate notes.  We also gave a list of [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/taking-biotech-etfs-ishares-nasdaq-biochnology-to-100-ibb-osip-mdvn.html</link>
			</item>
	<item>
		<title>Biotech Implosion: Medivation, Alzheimer&#8217;s Beats Drug (MDVN, PFE)</title>
		<description><![CDATA[Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion.  The company&#8217;s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.
The company did note that a separate Phase 3 safety study demonstrated [...]]]></description>
		<link>http://www.biohealthinvestor.com/2010/03/biotech-implosion-medivation-alzheimers-beats-drug-mdvn-pfe.html</link>
			</item>
</channel>
</rss>
